{Reference Type}: Journal Article
{Title}: The role of topical imiquimod in melanoma cutaneous metastases: A critical review of the literature.
{Author}: Scarfì F;Patrizi A;Veronesi G;Lambertini M;Tartari F;Mussi M;Melotti B;Dika E;
{Journal}: Dermatol Ther
{Volume}: 33
{Issue}: 6
{Year}: 11 2020
{Factor}: 3.858
{DOI}: 10.1111/dth.14165
{Abstract}: Despite of the emerging new systemic and local oncologic treatments (immunotherapy and checkpoint inhibitors, oncolytic viral treatments and injected immunostimulants) the management of skin melanoma metastasis can be still challenging. The main aim of this review was to assess the efficacy and the role of imiquimod in local metastatic melanoma disease. An extensive literature review was performed from September 2000 to March 2020 using PubMed, MEDLINE, Embase, and Cochrane Library databases. Selected articles regarded topical imiquimod, its mode of action as an antitumoral agent and its applications in melanoma metastases treatment. We analyzed a total of 18 published article of clinical cases and small case series and five studies: two retrospective large case series, two Phase I and II clinical trials and one cohort non randomized study. Generally, the treatment is safe and well tolerated. Imiquimod lead to an unstable locoregional control. The use of topical imiquimod for the treatment of MM cutaneous metastases should be considered in selected cases and in palliative settings.